HK Stock Market Move | ALPHAMAB-B(09966) rose more than 4%. New drug JSKN027 clinical trial application accepted.

ALPHAMAB-B(09966) rose more than 4%, as of the time of publication, it increased by 4.4%, reaching 10.68 Hong Kong dollars, with a turnover of 2.7829 million Hong Kong dollars. On the news front, on the evening of December 17th, Kangning Gerui Biopharmaceutical announced that the company's independently developed PD-L1/VEGFR2 bispecific antibody-drug conjugate (ADC) drug JSKN027's new drug clinical trial (IND) application has been formally accepted by the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE), and is about to begin Phase I clinical research for advanced malignant solid tumors. Currently, there are no ADCs globally targeting VEGFR2 alone or targeting both PD-L1 and VEGFR dual pathways in clinical research. JSKN027 is the world's first PD-L1/VEGFR2 bispecific ADC drug to enter clinical research. Preclinical data shows that JSKN027 exhibits significant tumor inhibitory activity in both in vitro and in vivo models.